Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Renal fibrosis plays an important role in the onset and progression of chronic kidney diseases (CKD). Although several mechanisms underlying renal fibrosis and candidate drugs for its treatment have been identified, the effect of iron chelator on renal fibrosis remains unclear. In the present study, we examined the effect of an iron chelator, deferoxamine (DFO), on renal fibrosis in mice with surgically induced unilateral ureter obstruction (UUO). Mice were divided into 4 groups: UUO with vehicle, UUO with DFO, sham with vehicle, and sham with DFO. One week after surgery, augmented renal tubulointerstitial fibrosis and the expression of collagen I, III, and IV increased in mice with UUO; these changes were suppressed by DFO treatment. Similarly, UUO-induced macrophage infiltration of renal interstitial tubules was reduced in UUO mice treated with DFO. UUO-induced expression of inflammatory cytokines and extracellular matrix proteins was abrogated by DFO treatment. DFO inhibited the activation of the transforming growth factor-β1 (TGF-β1)-Smad3 pathway in UUO mice. UUO-induced NADPH oxidase activity and p22(phox) expression were attenuated by DFO. In the kidneys of UUO mice, divalent metal transporter 1, ferroportin, and ferritin expression was higher and transferrin receptor expression was lower than in sham-operated mice. Increased renal iron content was observed in UUO mice, which was reduced by DFO treatment. These results suggest that iron reduction by DFO prevents renal tubulointerstitial fibrosis by regulating TGF-β-Smad signaling, oxidative stress, and inflammatory responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [67]
In the citing paper
“After a surgically induced unilateral ureter obstruction (UUO), mice treated with DFO showed significantly less fibrotic progression, less interstitial macrophage infiltration, and thereby a reduced expression of IL-1β and MCP-1 and a suppressed UUO-induced accumulation of myofibroblasts, compared with untreated mice.”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290 · cited 1×
“In addition, activated fibroblasts (also known as myofibroblasts) that express aSMA are a major source of extracellular matrix production [44].”
BackgroundThe Transforming Growth Factor-beta Family
Massague, J. (1990) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.06.110190.003121 · Cited by 3,015 · cited 1×
“Indeed, TGF-b1 is a well-known major profibrotic stimulator of collagen and extracellular matrix production in a variety of cell types [38].”
BackgroundMassagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355 · cited 1×
“[9,10], and that iron reduction therapy can ameliorate these disorders [7,8,11,12].”
BackgroundHypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976
Ferritins: A family of molecules for iron storage, antioxidation and more
Arosio, P., Ingrassia, R., & Cavadini, P. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.004 · Cited by 886 · cited 1×
“Ferritin, an intracellular iron storage protein, reduces intracellular free iron levels, thereby suppressing catalysis of the Fenton reaction [61].”
BackgroundSato, M., Muragaki, Y., Saika, S., Roberts, A. B., & Ooshima, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19270 · Cited by 831 · cited 2×
“Similar to its role in fibrosis, TGF-b1-Smad3 signaling is a key mediator for triggering EMT in vivo [42].”
BackgroundOberg, B. P., McMenamin, E., Lucas, F. L., McMonagle, E., Morrow, J., Ikizler, T. A. L. P., & Himmelfarb, J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00465.x · Cited by 781 · cited 1×
“Oxidative stress is considered a contributing factor in the progression of CKD, including renal fibrosis [49].”
BackgroundWang, G., & Semenza, G. (1993) · Blood · doi:10.1182/blood.v82.12.3610.3610 · Cited by 766
Research works printed but not linked: 1
- G Cairo, 2002, The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage, Free Radic Biol Med, 32, 1237
Cited by
Bayır, H., Dixon, S. J., Tyurina, Y. Y., Kellum, J. A., & Kagan, V. E. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00689-x · Cited by 331
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis
Handa, P., Thomas, S., Morgan-Stevenson, V., Maliken, B. D., Gochanour, E., Boukhar, S., Yeh, M. M., & Kowdley, K. V. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0318-108r · Cited by 217
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · Immunologic Research · doi:10.1007/s12026-020-09145-5 · Cited by 208
Current health risk assessment practice for dietary cadmium: Data from different countries
Satarug, S., Vesey, D. A., & Gobe, G. C. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.06.013 · Cited by 203
Metadata
- Authors
- Ikeda, Y., Ozono, I., Tajima, S., Imao, M., Horinouchi, Y., Izawa-Ishizawa, Y., Kihira, Y., Miyamoto, L., Ishizawa, K., Tsuchiya, K., & Tamaki, T.
- Affiliations
- Tokushima University (JP)
- Corresponding author
- Ikeda, Yasumasa
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-19
- Volume
- 9
- Issue
- 2
- Pages
- e89355
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3929716
- OpenAlex
- W1977079786
- Cited by
- 98
- References
- 62
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 10 · 2023: 7 · 2022: 11 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 6 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 1
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Osaka Foundation for Promotion of Fundamental Medical Research
- Japan Society for the Promotion of Science (24790254, 24591203, 25860063)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- deferoxamine, iron chelation, tubulointerstitial fibrosis, unilateral ureteral obstruction, chronic kidney disease, TGF-β1/Smad3 signaling, oxidative stress, NADPH oxidase, macrophage infiltration, inflammation, extracellular matrix, iron metabolism, ferroportin, ferritin, transferrin receptor, DMT1
- MeSH terms
- Animals, Deferoxamine, Fibrosis, Immunohistochemistry, Iron Chelating Agents, Kidney Diseases, Ureteral Obstruction, Blotting, Western, Signal Transduction, Chelation Therapy, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction. https://app.cochat.ai/papers/10.1371/journal.pone.0089355
- The paper
- Ikeda, Y., Ozono, I., Tajima, S., Imao, M., Horinouchi, Y., Izawa-Ishizawa, Y., Kihira, Y., Miyamoto, L., Ishizawa, K., Tsuchiya, K., & Tamaki, T. (2014). Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction. PLoS ONE. https://doi.org/10.1371/journal.pone.0089355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.